Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2025
Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering.
The report delivers a comprehensive insight into the current landscape of clinical trials focused on Atopic Dermatitis (Atopic Eczema) worldwide. Leveraging data from the proprietary Pharma - Clinical trials database, the report encapsulates a broad spectrum of clinical trial information, presenting crucial statistics such as trial numbers and average enrollment across leading countries globally. This robust database aggregates information from over 80 diverse sources including clinical trial registries, conferences, journals, and news outlets, ensuring a meticulously updated repository of data.
The report's extensive coverage includes detailed insights broken down by region and country (G7 & E7), trial phase, trial status, endpoints, and sponsor type. It highlights active trials and the significant drugs that are currently under investigation, aligning strategic interests with ongoing developments in the field of Atopic Dermatitis (Atopic Eczema).
Benefits of engaging with this report extend to enhancing decision-making capabilities, crafting strategic responses, and securing a competitive market advantage. Although some sections may be adapted based on data availability and relevance, the offering continues to provide an indispensable tool for stakeholders aiming to navigate the clinical trials landscape effectively.
Scope:
Presents a snapshot of the global clinical trials environment.
Delivers top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
Evaluates leading companies and lists trials (title, phase, and status) associated with them.
Documents all unaccomplished trials (terminated, suspended, and withdrawn), including reasons for their cessation.
Analyzes enrollment trends over the past five years.
Reports on the latest relevant news from the last three months.
Key Topics Covered:
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries
Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials
Clinical Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by E7 Countries
Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials
Clinical Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Clinical Trials by Sponsor Type
Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema)
Clinical Trial Profile Snapshots
A selection of companies mentioned in this report includes, but is not limited to:
Pfizer Inc
Novartis AG
Sanofi
Regeneron Pharmaceuticals Inc
LEO Foundation
Eli Lilly and Co
AbbVie Inc
Johnson & Johnson
Innovaderm Research Inc
Thermo Fisher Scientific Inc
For more information about this report visit https://www.researchandmarkets.com/r/br5r75
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
AAPL LOSS ALERT: Apple Inc. Investors with Losses are Reminded of the August 19 Class Action Deadline – Contact BFA Law (NASDAQ:AAPL)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Apple Inc. (NASDAQ: AAPL) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Apple, you are encouraged to obtain additional information by visiting: Investors have until August 19, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Apple securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Tucker v. Apple Inc., et al. , No. 5:25-cv-05197. Why was Apple Sued for Securities Fraud? Apple is a multinational technology company that engages primarily in the businesses of smart-devices and artificial intelligence ('AI'). Apple's software includes a digital personal assistant called 'Siri,' which was first introduced in October 2011. The complaint alleges that Apple misrepresented Siri's advanced AI-based features as well as its ability to deliver them within the iPhone 16 product cycle. In truth, as alleged, Apple lacked a functional prototype of Siri's purported advanced AI-based features and misrepresented the time it would take to integrate such features into its devices. The Stock Declines as the Truth is Revealed On March 7, 2025, Apple announced it was indefinitely delaying several AI-based Siri features, citing development delays and pushing their release to sometime 'in the coming year.' On this news, the price of Apple stock declined $11.59 per share, or almost 5%, from $239.07 per share on March 7, 2025, to $227.48 per share on March 10, 2025, the following trading day. Then, on June 9, 2025, Apple hosted its Worldwide Developer Conference for 2025. Noticeably, Apple failed to announce any new updates regarding advanced Siri features. Analysts and media outlets described the WWDC as 'underwhelming' and 'disappointing,' with CNN stating that 'it's unlikely that any of the announcements made at Monday's event will change the perception that Apple is behind its competitors in AI.' On this news, the price of Apple stock declined $2.47 per share, or over 1%, from $203.92 on June 6, 2025, to $201.45 per share on June 9, 2025, the following trading day. Click here for more information: What Can You Do? If you invested in Apple you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619
Business Upturn
2 hours ago
- Business Upturn
LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Lineage, Inc. (NASDAQ: LINE) and certain of the Company's senior executives and directors for potential violations of the federal securities laws. If you invested in Lineage, you are encouraged to obtain additional information by visiting: Investors have until September 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to Lineage's registration statement for its initial public offering held on or about July 25, 2024. The case is pending in the U.S. District Court for the Eastern District of Michigan and is captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al. , No. 2:25-cv-12383. Why Was Lineage Sued Under the Federal Securities Laws? Lineage is a cold storage focused real estate investment trust ('REIT'). Through its Global Warehousing Segment, Lineage owns and operates hundreds of temperature-controlled storage facilities used by companies to store food and other perishable products. As alleged, Lineage's IPO documents touted its 'consistent cold chain demand,' which purportedly provided Lineage 'with strong cash flows even during periods of broader economic stress.' The IPO documents also represented that the lingering effects of the COVID-19 pandemic had 'accelerated trends that . . . have the potential to be growth engines for the industry in coming years.' In truth, Lineage was allegedly in the midst of a sustained downturn, as its customers destocked excess inventory built up during the COVID-19 pandemic, and also shifted to leaner inventories on a go-forward basis and as more cold-storage supply came on line. Events Following the IPO On February 26, 2025, Lineage announced its fiscal Q4 2024 financial results, revealing that customers had been 'unwinding' previously 'overbuil[t]' levels of inventory, returning to a 'more normal seasonal pattern' that was expected to 'continue moving forward.' Lineage conducted its IPO at $78 per share. Since the IPO, the price of Lineage stock has fallen dramatically, to lows near $40 per share—approximately half the IPO price. Click here for more information: What Can You Do? If you invested in Lineage you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619
Business Upturn
2 hours ago
- Business Upturn
CNC LOSS ALERT: Centene Corporation Investors with Losses are Reminded of the September 8 Class Action Deadline – Contact BFA Law (NYSE:CNC)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: Investors have until September 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al. , No. 25-cv-05659. Why was Centene Sued for Securities Fraud? Centene is a healthcare company that focuses on providing services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace. On December 12, 2024, Centene announced financial guidance for fiscal year 2025 which the company said reflected '[s]tability in earnings power in the face of unprecedented headwinds.' Next, on February 4, 2025, Centene increased its 2025 guidance due to enrollment 'overperformance.' Then, on April 25, 2025, Centene again increased 2025 guidance due to continued strong growth in enrollment and retention, while touting the 'progress we are making as an organization while navigating a dynamic policy landscape.' In truth, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness. The Stock Declines as the Truth is Revealed On July 1, 2025, Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. On this news, the price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025. Click here for more information: What Can You Do? If you invested in Centene you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619
